{
    "id": 1629,
    "fullName": "KIT D816V",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIT D816V lies within the tyrosine kinase domain 2 of the Kit protein (PMID: 19865100). D816V results in constitutive phosphorylation of Kit, activation of Stat5 signaling (PMID: 19865100, PMID: 18390729), induces mastocytosis and tumor formation in mice (PMID: 21148330) and confers resistance to Kit inhibitors (PMID: 22301675, PMID: 19164557).",
            "references": [
                {
                    "id": 655,
                    "pubMedId": 19164557,
                    "title": "KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19164557"
                },
                {
                    "id": 671,
                    "pubMedId": 21148330,
                    "title": "Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21148330"
                },
                {
                    "id": 652,
                    "pubMedId": 18390729,
                    "title": "Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18390729"
                },
                {
                    "id": 646,
                    "pubMedId": 19865100,
                    "title": "Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19865100"
                },
                {
                    "id": 3820,
                    "pubMedId": 22301675,
                    "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22301675"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "D816V",
    "createDate": "09/09/2014",
    "updateDate": "09/14/2018",
    "referenceTranscriptCoordinates": {
        "id": 136086,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54733155A>T",
        "cDna": "c.2447A>T",
        "protein": "p.D816V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14343,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT D816V were resistant to treatment with Sutent (sunitinib) in culture (PMID: 24205792).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 663,
                    "pubMedId": 24205792,
                    "title": "Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24205792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3575,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KIT D816V mutations demonstrated resistance to Sutent (sunitinib) in a biochemical assay (PMID: 19164557).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 655,
                    "pubMedId": 19164557,
                    "title": "KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19164557"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8707,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT D816V were sensitive to BPR1J373, demonstrating inhibition of Kit phosphorylation (PMID: 27512117).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 4798,
                "therapyName": "BPR1J373",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6711,
                    "pubMedId": 27512117,
                    "title": "BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27512117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3601,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Quizartinib in culture (PMID: 23497317).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3862,
                    "pubMedId": 23497317,
                    "title": "Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23497317"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17999,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) did not inhibit Kit phosphorylation or growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17991,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3579,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Gleevec (imatinib mesylate) in culture (PMID: 15790786).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 425,
                    "pubMedId": 15790786,
                    "title": "Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15790786"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18465,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT D816V were sensitive to treatment with Ayvakit (avapritinib) in culture, demonstrating decreased cell proliferation (PMID: 31270078).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14245,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FF-10101, as compared to Quizartinib, inhibited cell proliferation of transformed 32Dcl3 murine myeloid cells expressing human Kit D816V (PMID: 29187377).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 7085,
                "therapyName": "FF-10101",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11567,
                    "pubMedId": 29187377,
                    "title": "A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29187377"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3577,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) decreased viability of cells expressing KIT D816V in culture, but did not inhibit KIT phosphorylation or growth of KIT D816V-expressing tumors in mouse models (PMID: 20442311).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3260,
                    "pubMedId": 20442311,
                    "title": "Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20442311"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17998,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) did not inhibit Kit phosphorylation or growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3613,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with acute myeloid leukemia harboring KIT D816V achieved long-term remission and loss of KIT D816V following treatment with the combination of Sprycel (dasatinib) and Cytosar-U (cytarabine) (PMID: 18986703).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 3174,
                "therapyName": "Cytarabine + Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3887,
                    "pubMedId": 18986703,
                    "title": "Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18986703"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18591,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of transformed cells expressing KIT D816V in culture (PMID: 31085175).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 4316,
                "therapyName": "Ripretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17997,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17994,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) demonstrated moderate inhibition of Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17995,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21186,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT D816V were sensitive to treatment with Sprycel (dasatinib) in culture, demonstrating reduced cell survival (PMID: 31182436).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18452,
                    "pubMedId": 31182436,
                    "title": "Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31182436"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13095,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, patients with either aggressive systemic mastocytosis, mast cell leukemia, or systemic mastocytosis with an associated hematologic neoplasm harboring KIT D816V demonstrated a reduction in mast cell burden and a decrease in KIT D816V allelic fraction when treated with Ayvakit (avapritinib) (ASH Annual Meeting, Dec 2017, Plenary 2).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3664,
                "name": "mast cell neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10963,
                    "pubMedId": null,
                    "title": "2 Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)",
                    "url": "https://ash.confex.com/ash/2017/webprogram/Paper102910.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1979,
            "approvalStatus": "FDA contraindicated",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Gleevec (imatinib) is not indicated for patients with aggressive systemic mastocytosis harboring KIT D816V (FDA.gov).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000005,
                "name": "Indication other than cancer",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15459,
                    "pubMedId": null,
                    "title": "Gleevec (imatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021588"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18000,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) demonstrated moderate inhibition of Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18592,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT D816V were resistant to Stivarga (regorafenib) in culture (PMID: 31085175).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14344,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT D816V were resistant to treatment with Flumatinib in culture (PMID: 24205792).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 3169,
                "therapyName": "Flumatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 663,
                    "pubMedId": 24205792,
                    "title": "Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24205792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17993,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) did not inhibit Kit phosphorylation or growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17989,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17996,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18463,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT D816V were sensitive to treatment with Rydapt (midostaurin) in culture, demonstrating decreased cell proliferation (PMID: 31270078).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3561,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematopoietic cells expressing KIT D816V demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 17229632).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3821,
                    "pubMedId": 17229632,
                    "title": "The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17229632"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17992,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) did not inhibit Kit phosphorylation or growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17990,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3585,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Cometriq (cabozantinib) in culture (PMID: 24205792).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 663,
                    "pubMedId": 24205792,
                    "title": "Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24205792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3560,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) did not inhibit growth of transformed cells expressing KIT D816V in culture (PMID: 22301675).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3820,
                    "pubMedId": 22301675,
                    "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22301675"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3580,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse myeloid cell line expressing KIT D816V demonstrated resistance to Gleevec (imatinib) in culture (PMID: 12481435).",
            "molecularProfile": {
                "id": 1643,
                "profileName": "KIT D816V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3853,
                    "pubMedId": 12481435,
                    "title": "Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12481435"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12301,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ayvakit (avapritinib) inhibited Kit phosphorylation and proliferation of a mast cell leukemia cell line harboring KIT D816V and V560G in culture (PMID: 29093181).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 9254,
                "name": "mast-cell leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10301,
                    "pubMedId": 29093181,
                    "title": "A precision therapy against cancers driven by KIT/PDGFRA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29093181"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18586,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited proliferation of mast cells harboring KIT D816V and KIT V560G in culture (PMID: 31085175).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 3664,
                "name": "mast cell neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8709,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mast-cell leukemia cell line simultaneously harboring KIT D816V and KIT V560G was sensitive to BPR1J373 in culture, demonstrating inhibition of Kit phosphorylation and apoptotic activity (PMID: 27512117).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 4798,
                "therapyName": "BPR1J373",
                "synonyms": null
            },
            "indication": {
                "id": 9254,
                "name": "mast-cell leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6711,
                    "pubMedId": 27512117,
                    "title": "BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27512117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18590,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mast cells harboring both KIT D816V and KIT V560G were resistant to Stivarga (regorafenib) in culture (PMID: 31085175).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3664,
                "name": "mast cell neoplasm",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3592,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of a human mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 24552773).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9254,
                "name": "mast-cell leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3870,
                    "pubMedId": 24552773,
                    "title": "Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing \u03b2-catenin signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24552773"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3600,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KIT D816V conferred resistance to Quizartinib in a mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 23497317).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3664,
                "name": "mast cell neoplasm",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3862,
                    "pubMedId": 23497317,
                    "title": "Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23497317"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18588,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mast cells harboring both KIT D816V and KIT V560G were resistant to Gleevec (imatinib) in culture (PMID: 31085175).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3664,
                "name": "mast cell neoplasm",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3562,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis in a mast-cell leukemia cell line harboring both KIT V560G and KIT D816V in culture (PMID: 18024392).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9254,
                "name": "mast-cell leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3822,
                    "pubMedId": 18024392,
                    "title": "Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18024392"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18589,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mast cells harboring both KIT D816V and KIT V560G were resistant to Sutent (sunitinib) in culture (PMID: 31085175).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3664,
                "name": "mast cell neoplasm",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18587,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ayvakit (avapritinib) inhibited proliferation of mast cells harboring KIT D816V and KIT V560G in culture (PMID: 31085175).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3664,
                "name": "mast cell neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of mast cells harboring KIT D816V and KIT V560G in culture, and inhibited tumor growth in cell line xenograft models (PMID: 31085175).",
            "molecularProfile": {
                "id": 13758,
                "profileName": "KIT V560G KIT D816V"
            },
            "therapy": {
                "id": 4316,
                "therapyName": "Ripretinib",
                "synonyms": null
            },
            "indication": {
                "id": 3664,
                "name": "mast cell neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11050,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring KIT D816V and NRAS Q61R demonstrated progressive disease when treated with a combination of Mekinist (trametinib) and Keytruda (pembrolizumab) (PMID: 28514312).",
            "molecularProfile": {
                "id": 27900,
                "profileName": "KIT D816V NRAS Q61R"
            },
            "therapy": {
                "id": 1450,
                "therapyName": "Pembrolizumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9046,
                    "pubMedId": 28514312,
                    "title": "Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28514312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18470,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670I demonstrated resistance to treatment with Ayvakit (avapritinib) in culture (PMID: 31270078).",
            "molecularProfile": {
                "id": 33230,
                "profileName": "KIT T670I KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18454,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670I demonstrated a decreased response compared to cells expressing KIT D816V alone when treated with Rydapt (midostaurin) in culture (PMID: 31270078).",
            "molecularProfile": {
                "id": 33230,
                "profileName": "KIT T670I KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18457,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT N655K demonstrated resistance to treatment with Rydapt (midostaurin) in culture compared to cells expressing KIT D816V alone (PMID: 31270078).",
            "molecularProfile": {
                "id": 33231,
                "profileName": "KIT N655K KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18467,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT N655K demonstrated some sensitivity to treatment with Ayvakit (avapritinib) in culture (PMID: 31270078).",
            "molecularProfile": {
                "id": 33231,
                "profileName": "KIT N655K KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18459,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT Y672C demonstrated a decreased response compared to cells expressing KIT D816V alone when treated with Rydapt (midostaurin) in culture (PMID: 31270078).",
            "molecularProfile": {
                "id": 33232,
                "profileName": "KIT Y672C KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18468,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT Y672C demonstrated some sensitivity to treatment with Ayvakit (avapritinib) in culture (PMID: 31270078).",
            "molecularProfile": {
                "id": 33232,
                "profileName": "KIT Y672C KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18469,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT D677N demonstrated some sensitivity to treatment with Ayvakit (avapritinib) in culture (PMID: 31270078).",
            "molecularProfile": {
                "id": 33233,
                "profileName": "KIT D677N KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18461,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT D677N demonstrated resistance to treatment with Rydapt (midostaurin) in culture compared to cells expressing KIT D816V alone (PMID: 31270078).",
            "molecularProfile": {
                "id": 33233,
                "profileName": "KIT D677N KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18466,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT V654A demonstrated some sensitivity to treatment with Ayvakit (avapritinib) in culture (PMID: 31270078).",
            "molecularProfile": {
                "id": 33234,
                "profileName": "KIT V654A KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18452,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT V654A demonstrated resistance to treatment with Rydapt (midostaurin) in culture compared to cells expressing KIT D816V alone (PMID: 31270078).",
            "molecularProfile": {
                "id": 33234,
                "profileName": "KIT V654A KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18472,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670V demonstrated some resistance to treatment with Ayvakit (avapritinib) in culture (PMID: 31270078).",
            "molecularProfile": {
                "id": 33240,
                "profileName": "KIT T670V KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18474,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670V were sensitive to treatment with Rydapt (midostaurin) in culture, demonstrating decreased cell proliferation (PMID: 31270078).",
            "molecularProfile": {
                "id": 33240,
                "profileName": "KIT T670V KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18473,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670A were sensitive to treatment with Rydapt (midostaurin) in culture, demonstrating decreased cell proliferation (PMID: 31270078).",
            "molecularProfile": {
                "id": 33241,
                "profileName": "KIT T670A KIT D816V"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18471,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670A demonstrated sensitivity to treatment with Ayvakit (avapritinib) in culture (PMID: 31270078).",
            "molecularProfile": {
                "id": 33241,
                "profileName": "KIT T670A KIT D816V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16200,
                    "pubMedId": 31270078,
                    "title": "ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31270078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1643,
            "profileName": "KIT D816V",
            "profileTreatmentApproaches": [
                {
                    "id": 7056,
                    "name": "Dasatinib",
                    "profileName": "KIT D816V"
                },
                {
                    "id": 7055,
                    "name": "Avapritinib",
                    "profileName": "KIT D816V"
                }
            ]
        },
        {
            "id": 13758,
            "profileName": "KIT V560G KIT D816V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27900,
            "profileName": "KIT D816V NRAS Q61R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33230,
            "profileName": "KIT T670I KIT D816V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33231,
            "profileName": "KIT N655K KIT D816V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33232,
            "profileName": "KIT Y672C KIT D816V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33233,
            "profileName": "KIT D677N KIT D816V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33234,
            "profileName": "KIT V654A KIT D816V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33240,
            "profileName": "KIT T670V KIT D816V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33241,
            "profileName": "KIT T670A KIT D816V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136086,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54733155A>T",
            "cDna": "c.2447A>T",
            "protein": "p.D816V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136087,
            "transcript": "NM_001093772",
            "gDna": "chr4:g.54733167A>T",
            "cDna": "c.2447A>T",
            "protein": "p.D816V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136089,
            "transcript": "XM_017008179",
            "gDna": "chr4:g.54733167A>T",
            "cDna": "c.2447A>T",
            "protein": "p.D816V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136088,
            "transcript": "XM_005265741",
            "gDna": "chr4:g.54733155A>T",
            "cDna": "c.2447A>T",
            "protein": "p.D816V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}